Menu
×
×

Sign Up

Your Profile will be reviewed by Admin
TODAY : Advanced Search
EVENT DATES
Jan 2018
MoTuWeThFrSaSu
1234567
891011121314
15161718192021
22232425262728
293031    
EXHIBITION HALL DATES
Jan 2018
MoTuWeThFrSaSu
1234567
891011121314
15161718192021
22232425262728
293031    

Venue

Moscone Center 747 Howard Street 5th Floor San Francisco , California 94103
Tel: (415) 974-4000
Website
Google Map

2018 Gastrointestinal Cancers Symposium

3,500 70

Overview

Event Overview:

Register for the Gastrointestinal Cancers Symposium and join us for three days of translational research, novel clinical therapies, and state-of-the-art science in GI oncology.

The Gastrointestinal (GI) Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community. This three-day meeting encompasses the latest science in cancers of the esophagus and stomach; the pancreas, small bowel, and hepatobiliary tract; and the colon, rectum, and anus. This year’s Symposium offers new breakout sessions covering cutting-edge and controversial topics, a networking luncheon for early-career oncologists, and the opportunity to view and discuss selected posters with respected faculty members during poster walks.

Exhibitor Information:

The exhibits at the Gastrointestinal Cancers Symposium highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet with representatives from the healthcare industry, including pharmaceutical companies and advocacy groups.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

ASCO Promotes and Provides For

    Lifelong learning for oncology professionals,
    Cancer research,
    An improved environment for oncology practice,
    Access to quality cancer care,
    A global network of oncology expertise, and
    Educated and informed patients with cancer.

ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer.

Agenda

Jan 18   

7:00 AM-8:00 AM

Complimentary Continental Breakfast

7:00 AM-6:30 PM

Exhibits Open

7:50 AM-9:30 AM

Welcome and General Session 1: Response Assessment and Individualization of Management of Esophageal Adenocarcinoma (ARS)

Sarah E. Hoffe, MD - Chair
H. Lee Moffitt Cancer Center and Research Institute

Gail Elizabeth Darling, MD - Chair
University of Toronto

Laura A. Dawson, MD
Princess Margaret Cancer Centre
Welcome of the Day

Case Presentation

Kenneth Wang, MD
Mayo Clinic
Initial Staging and Response Assessment

Debate: Management of Esophageal Adenocarcinoma After Neoadjuvant Therapy With Complete Clinical Response—Surgery Versus Watchful Waiting

Andrew Barbour, MBBS, PhD, FRACS, FACS
University of Queensland
Surgeon Perspective

Florence Huguet, MD, PhD
Hôpital Tenon
Radiation Oncologist Perspective

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
Improving Esophageal Adenocarcinoma Outcomes: Future Directions

Panel Question and Answer

9:30 AM-10:00 AM

Break

10:00 AM-11:30 AM

General Session 2: Global Outlook on Gastric Cancer

Ulysses Ribeiro Jr., MD, PhD - Chair
University of São Paulo

Khaldoun Almhanna, MD, MPH - Chair
Moffitt Cancer Center

Global Perspectives on Surveillance, Risk Factors, and Management of Early Gastric Cancer

Alexander G. Meining, MD
Medical School of the University of Ulm
European Perspective

Paola Catherine Montenegro, MD
Instituto Nacional de Enfermedades Neoplasicas
South American Perspective

Seiichiro Abe, MD
National Cancer Center Hospital
Asian Perspective

Margaret Gulley, MD
University of North Carolina School of Medicine
Capitalizing on Epstein-Barr Virus to Better Classify, Treat, and Monitor Gastric Cancer

 

Abstract 1: Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer: CCOG 1102.

First author: Daishi Morimoto, MD 

Panel Question and Answer

11:30 AM-1:00 PM

Poster Session A: Cancers of the Esophagus and Stomach
With Complimentary Boxed Lunch

11:30 AM-1:00 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

12:00 PM-1:00 PM

Trainee and Early-Career Networking Luncheon
For a full list of participating faculty, please visit the Trainee & Early-Career Networking Luncheon page

1:00 PM-2:00 PM

Rapid-Fire Abstract Session: Cancers of the Esophagus and Stomach

Sarah E. Hoffe, MD - Chair
Moffitt Cancer Center

Ulysses Ribeiro, Jr., MD, PhD - Chair
University of Sao Paulo

 

Abstract 6: Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: A randomized controlled trial.

First author: Pieter van der Sluis, MD, PhD, Msc

 

Question and Answer

 

Abstract 91: A prospective multicenter trial of S-1 with lafutidine vs S-1 as adjuvant chemotherapy for gastric cancer in Japan: AEOLUS.

First author: Nozomu Machida, MD, PhD

 

Question and Answer

 

Abstract 8: CYTO-CHIP: Cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A propensity-score analysis from BIG RENAPE and FREGAT working groups.

First author: Pierre Emmanuel Bonnot, BA

 

Question and Answer

 

Abstract 9: Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma.

First author: Maria Svensson, MD, PhD Student 

 

Question and Answer

1:00 PM-2:00 PM

Breakout Session: Multidisciplinary Management of Less Common Gastroesophageal Tumors

Shishir Maithel, MD, FACS - Chair
Emory University Winship Cancer Institute

Ronald P. DeMatteo, MD, FACS
University of Pennsylvania Hospital
Guidelines for Perioperative Imatinib Therapy for Gastrointestinal Stromal Tumors

Field F. Willingham, MD, MPH
Emory University School of Medicine
Evaluation of Gastroesophageal Submucosal Lesions and Minimally Invasive Management Options

Panel Question and Answer

1:00 PM-2:00 PM

Breakout Session: FLOT or Not—Perioperative Management for Gastric Cancer

Salah-Eddin Al-Batran, MD
Institute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center
Pro

Jaffer A. Ajani, MD
University of Texas MD Anderson Cancer Center
Con

Panel Question and Answer

2:00 PM-2:15 PM

Break

2:15 PM-3:45 PM

Oral Abstract Session A: Cancers of the Esophagus and Stomach

David H. Ilson, MD, PhD - Chair
Memorial Sloan Kettering Cancer Center

K. Robert Shen, MD - Chair
Mayo Clinic

 

Abstract 2: The impact of the chemoradiation to surgery interval on pathological complete response: Short and long-term overall survival in esophageal cancer patients.

First author: Basem Azab, BA

 

Abstract 3: Impact of lung and heart dose on survival after radiotherapy for esophageal cancer.

First author: Patrick Oh, BSc

 

Theodore S. Hong, MD

NSABP/ NRG Oncology/ Massachusetts General Hospital

Discussion

 

Abstract 4: Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.

First author: Florian Lordick, MD

 

Late-Breaking Abstract 

 

Stephen Leong, MD

University of Colorado Comprehensive Cancer Center

Discussion 

 

Panel Question and Answer

3:45 PM-4:15 PM

Break

4:15 PM-5:30 PM

General Session 3: Is There a Role for Locoregional Therapies in Stage IV Esophageal and Gastric Cancers? (ARS)

Paola Catherine Montenegro, MD - Chair
Instituto Nacional de Enfermedades Neoplasicas

Manisha Palta, MD - Chair
Duke University Medical Center

Case Presentation and Discussion

Brian D. Badgwell, MD
University of Texas MD Anderson Cancer Center
Surgical Oncologist Perspective

Elena Elimova, MD
Princess Margaret Cancer Centre
Medical Oncologist Perspective

Maria A Hawkins, FRCR, MD, MRCP
CRUK/MRC Oxford Institute for Radiation Oncology
Radiation Oncologist Perspective

5:30 PM-6:30 PM

Poster Session A: Cancers of the Esophagus and Stomach
With Complimentary Wine and Cheese Reception

5:30 PM-6:30 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

5:45 PM-6:30 PM

Poster Walks

Open to all attendees. Meet at the Poster Assistance Desk. 

 

Khaldoun Almhanna, MD, MPH

Moffitt Cancer Center 

 

K. Robert Shen, MD

Mayo Clinic

Jan 19   

7:00 AM-8:00 AM

Complimentary Continental Breakfast

7:00 AM-6:30 PM

Exhibits Open

7:55 AM-9:30 AM

Welcome and General Session 4: Multimodality Management of Biliary Malignancies

Shishir Maithel, MD, FACS - Chair
Emory University Winship Cancer Institute

Ryan Fields, MD, FACS - Chair
Washington University School of Medicine in St. Louis

Karyn A. Goodman, MD, MS
University of Colorado Cancer Center
Welcome of the Day

Juan W. Valle, MD
The Christie Hospital NHS Foundation Trust
Current State of Adjuvant Therapy for Biliary Tract Malignancies

Robin Kate Kelley, MD
University of California San Francisco
Advances in Molecular Targeted Therapies in Cholangiocarcinoma

Charles Rosen, MD
Mayo Clinic
Liver Transplantation for Cholangiocarcinoma: Indications and Outcomes

Panel Question and Answer

9:30 AM-10:00 AM

Break

10:00 AM-11:30 AM

General Session 5: Emerging Options for Hepatocellular Carcinoma—A Global Perspective

Josep Llovet, MD, PhD - Chair
Icahn School of Medicine at Mount Sinai

Riccardo Lencioni, MD - Chair
University of Miami Sylvester Comprehensive Cancer Center

Massimo Colombo, MD
Humanitas Research Hospital
The Effect of New Antiviral Therapies for Hepatitis C on the Occurrence and Recurrence of Hepatocellular Carcinoma

Richard K. G. Do, MD, PhD
Memorial Sloan Kettering Cancer Center
Diagnosis and Assessment of Response in Hepatocellular Carcinoma: LI-RADS, RECIST, and mRECIST

Edward Kim, MD, FSIR
Icahn School of Medicine at Mount Sinai
Locoregional Therapy With Selective Internal Radiotherapy for Hepatocellular Carcinoma: Where Do We Stand?

Jinsil Seong, MD, PhD
Yonsei University College of Medicine
Stereotactic Body Radiotherapy: What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma?

Ann-Lii Cheng, MD, PhD
National Taiwan University Hospital
Systemic Therapy for Advanced Hepatocellular Carcinoma

Panel Question and Answer

11:30 AM-1:00 PM

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Boxed Lunch

11:30 AM-1:00 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

12:00 PM-12:45 PM

Poster Walks

Open to all attendees. Meet at the Poster Assistance Desk. 

 

Ryan Fields, MD, FACS

Washington University School of Medicine in St. Louis

 

Philip Agop Philip, MD, PhD, FRCP

Karmanos Caner Institute 

1:00 PM-2:00 PM

Rapid-Fire Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Jason C. Cheng, MD, MS, PhD  - Chair
National Taiwan University Hospital

Shishir Maithel, MD, FACS - Chair
Emory University Winship Cancer Institute

 

Abstract 208: A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).

First author: Ramesh Ramanathan, MD

 

Question and Answer

 

Abstract 209: KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.

First author: Andrew Zhu

 

Question and Answer

 

Abstract 210: Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial.

First author: Sang Min Yoon

 

Question and Answer

 

Abstract 211: Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657).

First author: Kyaw Aung, MBBS, MRCP, PhD

 

Question and Answer

1:00 PM-2:00 PM

Breakout Session: Hereditary Gastrointestinal Cancer Syndromes

Aimee Lucas, MD, MS
Icahn School of Medicine at Mount Sinai
Genetic Syndromes Associated With Increased Risk of Pancreaticobiliary and Gastroduodenal Cancers

Sonia Kupfer, MD
University of Chicago
Optimal Screening and Surveillance of Genetically High-Risk Individuals

Flavio G. Rocha, MD
Virginia Mason Hospital and Medical Center
Surgical Management of Cancers in Patients with a Genetic Predisposition

Panel Question and Answer

1:00 PM-2:00 PM

Breakout Session: Minimally Invasive Diagnostic and Interventional Techniques for Pancreaticobiliary Malignancies

James Farrell, MD
Yale School of Medicine, Yale University
Technologic Advances in Endoscopic Visualization of Cancer

Christopher J. Dimaio, MD
Icahn School of Medicine at Mount Sinai
Therapeutic Endoscopic Approaches to Pancreaticobiliary Tumors

Shailesh V. Shrikhande, MD, MS, FRCS
Tata Memorial Hospital
Minimally Invasive Surgical Approaches: Current Evidence

Panel Question and Answer

2:00 PM-2:15 PM

Break

2:15 PM-3:45 PM

Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Ryan Fields, MD, FACS  - Chair
Washington University School of Medicine in St. Louis

Flavio G. Rocha, MD  - Chair
Virginia Mason Hospital and Medical Center

 

Abstract 204: Phase II LAPACT Trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).

First author: Pascal Hammel

 

Abstract 205: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT).

First author: Chigusa Morizane, MD, PhD

 

Brian M. Wolpin, MD

Dana-Farber Cancer Institute

Discussion

 

Abstract 206: Randomized, Open Label, Multicenter, Phase II Trial comparing Transarterial Chemoembolization (TACE) plus Sorafenib with TACE Alone in Patients with Hepatocellular Carcinoma (HCC): TACTICS Trial.

First author: Masatoshi Kudo, MD, PhD

 

Abstract 207: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial.

First author: Ghassan Abou-Alfa, MD

 

Jordi Bruix, MD, PhD

University of Barcelona

Discussion 

 

Panel Question and Answer

3:45 PM-4:15 PM

Break

4:15 PM-5:30 PM

General Session 6: Advanced and Metastatic Neuroendocrine Tumors (ARS)

Philip Agop Philip, MD, PhD, FRCP - Chair
Karmanos Cancer Institute

Michelle Kang Kim, MD, PhD - Chair
Icahn School of Medicine at Mount Sinai

Case 1: Synchronous Metastatic Midgut Neuroendocrine Tumor

Case 2: Gastric Neuroendocrine Tumor

Case 3: Unresectable Pancreatic Neuroendocrine

Massimo Falconi, MD
Università Vita Salute - Ospedale San Raffaele
Surgeon Perspective

Marianne Pavel, MD
Friedrich-Alexander University Erlangen-Nürnberg
Endocrine/Oncology Perspective

Parag Parikh, MD
Washington University School of Medicine in St. Louis
Radiation Oncologist Perspective

Wolfgang Weber, MD
Technical University of Munich
Nuclear Medicine Perspective

Michael C. Soulen, MD
University of Pennsylvania
Interventional Radiologist Perspective

5:30 PM-6:30 PM

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
With Complimentary Wine and Cheese Reception

5:30 PM-6:30 PM

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Jan 20   

7:00 AM-7:55 AM

Rapid-Fire Abstract Session: Cancers of the Colon, Rectum, and Anus

Michael J. Hall, MD, MS - Chair
Fox Chase Cancer Center 

 

Abstract 557: Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.

First author: Kohei Shitara, MD

 

Question and Answer

 

Abstract 558: SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS.

First author: Mark Saunders, MD, PhD

 

Question and Answer

 

Abstract 559: Effect of physical activity trackers and daily text messages on quality-of-life in colorectal survivors (Smart Pace): A pilot randomized controlled trial.

First author: Hilary Chan, BA

 

Question and Answer

 

Abstract 560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

First author: Johanna Bendell, MD

 

Question and Answer

7:00 AM-7:55 AM

Poster Session C: Cancers of the Colon, Rectum, and Anus

7:00 AM-7:55 AM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

7:00 AM-7:55 AM

Breakout Session: Intraperitoneal Chemotherapy for Intra-abdominal Malignancies

Daniel Tandel Chang, MD - Chair
Stanford University School of Medicine

Debate: Colorectal Cancer With Peritoneal Metastasis—A Regional Disease Requiring Regional Therapy

Edward Allen Levine, MD
Wake Forest University
Pro

Garrett Michael Nash, MD, MPH
Memorial Sloan Kettering Cancer Center
Con

Steven Arthur Ahrendt, MD
University of Colorado School of Medicine
Appendiceal Tumors and Peritoneal Mesotheliomas

Panel Question and Answer

7:00 AM-7:55 AM

Breakout Session: Liquid Biopsies—Role in Management of Gastrointestinal Cancers

Ash A. Alizadeh, MD, PhD
Stanford Cancer Institute
Overview of Technology: Circulating Tumor Cells and DNA

Ryan Bruce Corcoran, MD, PhD
Massachusetts General Hospital
Clinical Implications of Liquid Biopsies

Panel Question and Answer

7:00 AM-7:55 AM

Complimentary Continental Breakfast

7:55 AM-9:30 AM

Welcome and General Session 7: Early-Onset Colorectal Cancer

Rodrigo Jover, MD, PhD - Chair
Alicante University General Hospital

Andrew T. Chan, MD, MPH - Chair
Massachusetts General Hospital/ Harvard Medical School

Shishir Maithel, MD, FACS
Emory University Winship Cancer Institute
Welcome of the Day

Joseph J.Y. Sung, MD, PhD, MBBS
The Chinese University of Hong Kong
Epidemiology of Early-Onset Colon Cancer

Fay Kastrinos, MD, MPH
Columbia University Medical Center
Health Disparities, Screening, and Prevention

Irit Ben-Aharon, MD, PhD
Davidoff Cancer Center
Clinical Management and Survivorship Issues

 

 

Abstract 552: Age distribution of tumor gene expression in patients with stage II/III colon cancer.

First author: Howard Hochster, MD



Panel Question and Answer

9:30 AM-10:00 AM

Break

10:00 AM-11:00 AM

Keynote Lecture: Mapping the Immune Landscape in Pancreatic Cancer

Steven D. Leach, MD
Dartmouth Norris Cotton Cancer Center

11:00 AM-12:30 PM

Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus

S. Gail Eckhardt, MD, FASCO - Chair
University of Colorado School of Medicine

Mary Uan-Sian Feng, MD  - Chair
University of California, San Francisco

 

Abstract 553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.

First author: Thierry Andre, MD

 

Abstract 554: Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.

First author: Michael Overman, MD

 

Zsofia Kinga Stadler, MD
Memorial Sloan Kettering Cancer Center

Discussion 

 

Abstract 555: Genetic profile of polyps and risk of advanced metachronous lesions.

First author: Oscar Murcia Sr., MD

 

Abstract 556: Prospective clinical study of circulating tumor cells for colorectal cancer screening.

First author: Wen-Sy Tsai, MD, PhD

 

Douglas Corley, MD, PhD, MPH
Kaiser Permanente

Discussion

 

Panel Question and Answer

12:30 PM-2:00 PM

Poster Session C: Cancers of the Colon, Rectum, and Anus
With Complimentary Boxed Lunch

12:30 PM-2:00 PM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

1:00 PM-1:45 PM

Poster Walks

Open to all attendees. Meet at the Poster Assistance Desk. 

 

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center

 

TBD

2:00 PM-3:00 PM

General Session 8: Controversies in Adjuvant Therapy for Colorectal Cancer (ARS)

Frank A. Sinicrope, MD - Chair
Mayo Clinic

Karyn A. Goodman, MD, MS - Chair
University of Colorado Cancer Center

Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough?

Jeffrey A. Meyerhardt, MD, MPH, FASCO
Dana-Farber Cancer Institute/ Partners Cancer Care
U.S. Perspective

Timothy Iveson, MD, FRCP
University Hospital Southampton NHS Foundation Trust
European Perspective

Role of (Neo)Adjuvant Chemotherapy for Rectal Cancer: U.S. Versus European Approach

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center
U.S. Perspective

Cornelis J. H. Van De Velde, MD, PhD
Leiden University Medical Center
European Perspective

Panel Question and Answer

3:00 PM-3:15 PM

Break

3:15 PM-4:30 PM

General Session 9: Contemporary Management of Colorectal Cancer Liver Metastases (ARS)

Flavio G. Rocha, MD - Chair
Virginia Mason Hospital and Medical Center

Michael J. Hall, MD, MS - Chair
Fox Chase Cancer Center

Case Presentation and Discussion

Guy A. Van Hazel, FRACP, FRCP, MBBS
Sir Charles Gairdner Hospital
Medical Oncologist Perspective

Alejandra Méndez Romero, MD, PhD
Erasmus Medical Center
Radiation Oncologist Perspective

Mark Hull, MD, PhD
University of Leeds
Clinician Scientist Perspective

Rene Adam, MD, PhD
Paul Brousse Hospital, France
Surgeon Perspective

Keynote Speakers

Steven D. Leach

MD

Andrew Zhu

Author

SERVICE PROVIDERS

RELATED EVENTS +

MORE events +